AMLX — Amylyx Pharmaceuticals, Inc.

Summary of Amylyx Pharmaceuticals Q1 2026 Earnings Call

1. Key Financial Results and Metrics:

• Cash and marketable securities at the end of Q1 2026 totaled $279.8 million, down from $317 million at the end of Q4 2025, providing a cash runway into 2028.
• Total operating expenses for Q1 2026 were $43.8 million, a 16% increase from Q1 2025.
• Research and development expenses rose to $27.6 million, primarily due to increased spending on the avexitide clinical trial.
• Selling, general, and administrative expenses were $16.2 million, slightly up from $15.7 million in Q1 2025, driven by consulting and professional services related to avexitide’s potential launch.
• Non-cash stock-based compensation decreased to $6.1 million from $6.8 million in the prior year.

2. Strategic Updates and Business Highlights:

• Progressing with the pivotal Phase III LUCIDITY trial of avexitide for post-bariatric hypoglycemia (PBH), with top-line data expected next quarter.
• NDA preparations are underway, with sections being drafted in anticipation of a potential submission post-trial results.
• Launch readiness for avexitide is being prioritized, including a disease state education campaign set to launch this summer.
• The company is also advancing other pipeline candidates, including AMX0318 and AMX0114, with upcoming data presentations expected.

3. Forward Guidance and Outlook:

• The company remains on track for top-line results from the LUCIDITY trial in Q3 2026, with potential FDA approval and commercial launch of avexitide anticipated in 2027.
• Continued focus on scaling the business and preparing for commercialization, with a strong emphasis on addressing the unmet needs in the PBH community.

4. Bad News, Challenges, or Points of Concern:

• The decrease in cash reserves may raise concerns about funding future operations and trials, although the current runway extends into 2028.
• The company faces the challenge of successfully executing the LUCIDITY trial and achieving positive results to support NDA submission.
• Potential risks include competition from other therapies and the need to effectively communicate the benefits of avexitide to a broad audience of healthcare providers.

5. Notable Q&A Insights:

• The initiation of an Expanded Access Program (EAP) for avexitide was discussed, highlighting the urgency to provide treatment options for patients with no current FDA-approved therapies.
• Questions regarding the variability of hypoglycemic events in the LUCIDITY trial were addressed, indicating that the study is designed to account for such variability.
• The presence of an ICD-10 code for PBH, effective October 2026, was noted as a positive development for tracking and identifying patients, although not deemed essential for commercialization.
• The company emphasized the importance of both Level 2 and Level 3 hypoglycemic events as clinically meaningful outcomes in the LUCIDITY trial, with plans to report these separately in the top-line data.
• Insights into the commercial strategy highlighted a focus on centers of excellence and key opinion leaders, with plans to expand outreach to the broader endocrinology community as education efforts progress.